Today's Trend
Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA) is trading lower today after a string of analyst updates that, while still positive overall, highlighted ongoing losses through 2026 and 2027.
Wedbush recently initiated coverage with an Outperform rating, which is a supportive sign for the stock. At the same time, HC Wainwright reiterated a Buy rating and a $45 price target, indicating Wall Street still sees meaningful upside from current levels.
- Wedbush started coverage on Damora Therapeutics with an Outperform rating, adding another bullish analyst view for the stock. Damora Therapeutics Receives Outperform Rating from Wedbush
- HC Wainwright maintained a Buy rating and a $45 price target, suggesting analysts believe DMRA remains undervalued relative to its long-term potential.
- HC Wainwright’s updated forecasts call for continued per-share losses in 2026 and 2027, with estimated EPS ranging from about $(0.32) to $(0.35) per quarter and full-year losses of $(1.51) in FY2026 and $(1.53) in FY2027.
Investor takeaway: DMRA’s decline appears tied more to profit-taking and the market’s focus on persistent expected losses than to any major negative company-specific event. The analyst coverage is still constructive, but the earnings outlook remains firmly negative, which may be weighing on sentiment.